

**CIRCULATING TUMOR CELLS (CTC) FOR COLORECTAL CANCER
BY CELLSEARCH, BLOOD
#89162**

USEFUL FOR: An aid in the monitoring of patients with metastatic colon cancer.

METHODOLOGY: Cell Search System

REFERENCE VALUES: An interpretive report will be provided.

SPECIMEN REQUIREMENTS: Using the Circulating Tumor Cell Collection Kit (Supply T630) supplied, submit 2 CellSave tubes each containing 7.5 mL of whole blood. **(Specimen drawn in a tube other than CellSave tube or specimen submitted for reasons other than monitoring metastatic colon cancer is not acceptable.)** Forward promptly on the same day of draw at ambient temperature only.

Blood samples must be collected into a CellSave tube and processed in the lab within 96 hours of collection.

Cautions: This test is only for monitoring colon cancer patients with metastatic disease. It is not FDA approved for colon cancer patients without metastatic disease.

Patients on Doxorubicin (Adriamycin) must wait a minimum of 7 days after administration before blood can be collected for this test.

The CellSearch System has also been FDA approved for breast and prostate cancer. For breast cancer order: #89089 Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch, Blood.

LIST FEE: \$726.00

CPT CODE: 88184/Flow cytometry, cell surface cytoplasmic
88185/x3 each additional marker
88187/x7 Flow Cytometry, interpretation; 2 to 8 markers

ANALYTIC TIME: 4 days

DAY(S) SET-UP: Sunday through Friday

QUESTIONS: Contact your Mayo Medical Laboratories' Regional Manager
Kim J. Baker, Mayo Medical Laboratories' Technologist Support
Telephone: 800-533-1710



TEST DEFINITION

8/4/2009

CODE NAME

89162 CIRCULATING TUMOR CELLS, COLORECTAL

ORDER CODE	EFF DATE	TC	TITLE	CHECKING NORMALS	PRINT NORMALS (# CODED)	PERFORM SITE *
89162	7/8/2009		CIRCULATING TUMOR CELLS, COLORECTAL			MCR
		50803	TRANSPORT TEMP : AMBIENT\REFRIG NO\FROZEN NO SPECIMEN			
		50804	SPECIMEN ID			
		50805	SOURCE			
		50806	ORDER DATE			
		50807	REASON FOR REFERRAL			
		50808	METHOD			
		50809	RESULT			
		50810	INTERPRETATION			
		50811	AMENDMENT			
		50812	REVIEWED BY			
		50813	RELEASE DATE			

*PERFORMING SITE LEGEND

=====
 ==
 MCR MAYO CLINIC DPT OF LAB MED & PATHOLOGY
 200 FIRST STREET SW
 ROCHESTER, MN 55905

LAB DIRECTOR: FRANKLIN R. COCKERILL, III, M.D.

=====
 ==



LABORATORY SERVICE REPORT

1-800-533-1710

PATIENT NAME TESTING, CTCCQA		PATIENT NUMBER		AGE 33	SEX F	ACCESSION # G9132692
ORDERING PHYSICIAN			CLIENT ORDER #			ACCOUNT # C7022514
COLLECTION 07/27/09 07:10 A	RECEIVED 07/27/09 07:10 A	REPORT PRINTED 08/04/09 12:39 P		SPECIMEN INFORMATION DATE OF BIRTH:		
DATE	TIME	DATE	TIME	DATE	TIME	
TESTING MAYONET AND I AM TESTING A LONG OBRRRRRRRR ATTN: Hilton 5 Testing MayoNet Rochester, MN 55905 538-0528						

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *
----------------	----------	-----------	----------------

Circulating Tumor Cells, Colorectal

Specimen	Whole Blood	MCR
Specimen ID	1047384	MCR
Order Date	28 Jul 2009 13:19	MCR
Reason For Referral		MCR
Assess for Circulating Tumor Cells		
Method		MCR
CellSearch (TM) System		
Result		MCR
Negative, 2 circulating tumor cells/7.5 mL of blood.		
Interpretation		MCR

The results of this test are negative (<3 circulating tumor cells/7.5 mL of blood).

In patients with metastatic colon cancer, negative results are predictive of longer progression-free survival (PFS). In one prospective multicenter study, circulating tumor cells (CTCs) were enumerated in the peripheral blood of 430 patients with metastatic colorectal cancer at baseline and after starting first-, second-, or third-line therapy. CTCs were measured using an immunomagnetic separation technique. Patients were stratified into unfavorable and favorable prognostic groups based on CTC levels of three or more or less than three CTCs/7.5 mL, respectively. Patients with unfavorable compared with favorable baseline CTCs had shorter median progression-free survival (PFS; 4.5 v 7.9 months; P = .0002) and overall survival (OS; 9.4 v 18.5 months; P < .0001). Differences persisted at 1 to 2, 3 to 5, 6 to 12, and 13 to 20 weeks after therapy. Conversion of baseline unfavorable CTCs to favorable at 3 to 5 weeks was associated with significantly longer PFS and OS compared with patients with unfavorable CTCs at both time points

* Perform Site Legend on last page of report

PATIENT NAME TESTING, CTCCQA	ORDER STATUS Final	COLLECTION DATE AND TIME 07/27/09 07:10 A
---------------------------------	-----------------------	----------------------------------------------

Specimen receipt and report times are in CST/CDT

REPRINT

Page 1 of 2

08/04/2009 12:40PM



LABORATORY SERVICE REPORT

1-800-533-1710

PATIENT NAME TESTING, CTCCQA		PATIENT NUMBER		AGE 33	SEX F	ACCESSION # G9132692
ORDERING PHYSICIAN		CLIENT ORDER #				ACCOUNT # C7022514
COLLECTION 07/27/09 07:10 A	RECEIVED 07/27/09 07:10 A	REPORT PRINTED 08/04/09 12:39 P		SPECIMEN INFORMATION DATE OF BIRTH:		
DATE	TIME	DATE	TIME			
TESTING MAYONET AND I AM TESTING A LONG OBRRRRRRRR ATTN: Hilton 5 Testing MayoNet Rochester, MN 55905 538-0528						

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *
<p>(PFS, 6.2 v 1.6 months; P = .02; OS, 11.0 v 3.7 months; P = .0002). Among non-progressing patients, favorable compared with unfavorable CTCs within 1 month of imaging was associated with longer survival (18.8 v 7.1 months; P < .0001). Baseline and follow-up CTC levels remained strong predictors of PFS and OS after adjustment for clinically significant factors (Cohen SJ et al., J Clin Oncol. 26:3213-21, 2008.)</p>			
Reviewed By	Michael R Henry MD		MCR
Release Date	28 Jul 2009 15:13		MCR

* PERFORMING SITE

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First Street SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.
-----	-----------------------------------------------------------------------------------	------------------------------------------------

PATIENT NAME TESTING, CTCCQA	ORDER STATUS Final	COLLECTION DATE AND TIME 07/27/09 07:10 A
---------------------------------	-----------------------	----------------------------------------------

Specimen receipt and report times are in CST/CDT

REPRINT

Page 2 of 2